United Therapeutics (NASDAQ:UTHR) CEO Sells $5,393,530.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $567.74, for a total transaction of $5,393,530.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,000,850.62. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Down 1.5%

United Therapeutics stock opened at $562.09 on Friday. The business has a 50-day simple moving average of $565.98 and a two-hundred day simple moving average of $515.55. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The company has a market cap of $23.86 billion, a P/E ratio of 20.75, a P/E/G ratio of 1.84 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the previous year, the business posted $6.63 EPS. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics said it will present at the Jefferies Global Healthcare Conference, keeping the company visible to investors and highlighting ongoing engagement with the healthcare investing community. Article Title
• Positive Sentiment: The company also shared updates on its PHINDER screening study and its xenokidney/EXTEND trial, which could support the long-term growth story if the clinical programs continue to progress. Article Title Article Title
• Neutral Sentiment: The stock remains supported by a generally constructive analyst backdrop, with several firms maintaining buy or outperform ratings and some raising price targets, which can help offset near-term concerns.
• Neutral Sentiment: Short-interest data showed no meaningful change in available reported shares, so this does not appear to be a major trading catalyst.
• Negative Sentiment: CEO Martine Rothblatt sold additional United Therapeutics shares, following another recent sale, and CFO James Edgemond also sold stock. Multiple insider sales can weigh on investor sentiment, especially after the company’s recent earnings miss. Article Title Article Title
• Negative Sentiment: United Therapeutics recently reported quarterly EPS and revenue below expectations, which remains an overhang on the shares despite the company’s strong profitability.

Wall Street Analyst Weigh In

UTHR has been the subject of several research reports. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a report on Thursday, May 7th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Bank of America increased their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Finally, Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Institutional Trading of United Therapeutics

Several hedge funds have recently made changes to their positions in UTHR. AE Wealth Management LLC grew its stake in United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC grew its stake in United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after acquiring an additional 2,975 shares in the last quarter. Optimize Financial Inc bought a new position in United Therapeutics in the 3rd quarter worth about $444,000. Tobam grew its stake in United Therapeutics by 183.9% in the 3rd quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after acquiring an additional 4,953 shares in the last quarter. Finally, Leuthold Group LLC grew its stake in United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after acquiring an additional 3,126 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.